Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
J Gastrointest Oncol ; 13(5): 2633-2638, 2022 Oct.
Article in English | MEDLINE | ID: mdl-36388676

ABSTRACT

Background: The widespread use of cross-sectional imaging and ultrasound has led to an increase in the diagnosis of pancreatic cystic neoplasms. These lesions have an estimated prevalence of 2.4% of which approximately 10-16% are serous cystadenoma (SCA). SCA is the most common benign pancreatic lesion; the vast majority are asymptomatic and associated with low risk for malignant transformation. Despite improved insight into the natural history of these tumors, recommendations for their management remain contentious. We present two cases of giant SCA that call attention to shortcomings of the current guidelines for management of benign cystic pancreatic lesions. Case Description: In both cases, patients presented for surgical evaluation late in the disease course despite multiple medical consultations with generalist and specialty providers. Although both lesions were resected, their late presentation may have increased risk for complication and post-operative morbidity. Conclusions: These cases highlight possible discrepancies between medical and surgical perspectives in the field and support future investigation into more aggressive surgical management of SCA.

2.
Sci Rep ; 11(1): 1468, 2021 01 14.
Article in English | MEDLINE | ID: mdl-33446832

ABSTRACT

Normal growth and development of lymphatic structures depends on mechanical forces created by accumulating interstitial fluid. However, prolonged exposure to pathologic mechanical stimuli generated by chronically elevated lymph flow results in lymphatic dysfunction. The mechanisms that transduce these mechanical forces are not fully understood. Our objective was to investigate molecular mechanisms that alter the growth and metabolism of isolated lymphatic endothelial cells (LECs) exposed to prolonged pathologically elevated lymph flow in vivo within the anatomic and physiologic context of a large animal model of congenital heart disease with increased pulmonary blood flow using in vitro approaches. To this end, late gestation fetal lambs underwent in utero placement of an aortopulmonary graft (shunt). Four weeks after birth, LECs were isolated and cultured from control and shunt lambs. Redox status and proliferation were quantified, and transcriptional profiling and metabolomic analyses were performed. Shunt LECs exhibited hyperproliferative growth driven by increased levels of Hypoxia Inducible Factor 1α (HIF-1α), along with upregulated expression of known HIF-1α target genes in response to mechanical stimuli and shear stress. Compared to control LECs, shunt LECs exhibited abnormal metabolism including abnormalities of glycolysis, the TCA cycle and aerobic respiration. In conclusion, LECs from lambs exposed in vivo to chronically increased pulmonary lymph flow are hyperproliferative, have enhanced expression of HIF-1α and its target genes, and demonstrate altered central carbon metabolism in vitro. Importantly, these findings suggest provocative therapeutic targets for patients with lymphatic abnormalities.


Subject(s)
Endothelial Cells/metabolism , Hypoxia-Inducible Factor 1, alpha Subunit/metabolism , Lymph/physiology , Animals , Cell Proliferation/drug effects , Disease Models, Animal , Female , Fetus/metabolism , Heart Defects, Congenital/metabolism , Lung/metabolism , Lung/pathology , Lymphatic Vessels/metabolism , Nitric Oxide/metabolism , Pregnancy , Primary Cell Culture , Pulmonary Circulation/physiology , Sheep/metabolism , Signal Transduction , Stress, Mechanical , Vascular Endothelial Growth Factor A/metabolism
3.
Pulm Circ ; 10(2): 2045894020922118, 2020.
Article in English | MEDLINE | ID: mdl-32489641

ABSTRACT

The risk and progression of pulmonary vascular disease in patients with congenital heart disease is dependent on the hemodynamics associated with different lesions. However, the underlying mechanisms are not understood. Endothelin-1 is a potent vasoconstrictor that plays a key role in the pathology of pulmonary vascular disease. We utilized two ovine models of congenital heart disease: (1) fetal aortopulmonary graft placement (shunt), resulting in increased flow and pressure; and (2) fetal ligation of the left pulmonary artery resulting in increased flow and normal pressure to the right lung, to investigate the hypothesis that high pressure and flow, but not flow alone, upregulates endothelin-1 signaling. Lung tissue and pulmonary arterial endothelial cells were harvested from control, shunt, and the right lung of left pulmonary artery lambs at 3-7 weeks of age. We found that lung preproendothelin-1 mRNA and protein expression were increased in shunt lambs compared to controls. Preproendothelin-1 mRNA expression was modestly increased, and protein was unchanged in left pulmonary artery lambs. These changes resulted in increased lung endothelin-1 levels in shunt lambs, while left pulmonary artery levels were similar to controls. Pulmonary arterial endothelial cells exposed to increased shear stress decreased endothelin-1 levels by five-fold, while cyclic stretch increased levels by 1.5-fold. These data suggest that pressure or an additive effect of pressure and flow, rather than increased flow alone, is the principal driver of increased endothelin signaling in congenital heart disease. Defining the molecular drivers of the pathobiology of pulmonary vascular disease due to differing mechanical forces will allow for a more targeted therapeutic approach.

4.
Am J Respir Cell Mol Biol ; 60(5): 503-514, 2019 05.
Article in English | MEDLINE | ID: mdl-30620615

ABSTRACT

The natural history of pulmonary vascular disease associated with congenital heart disease (CHD) depends on associated hemodynamics. Patients exposed to increased pulmonary blood flow (PBF) and pulmonary arterial pressure (PAP) develop pulmonary vascular disease more commonly than patients exposed to increased PBF alone. To investigate the effects of these differing mechanical forces on physiologic and molecular responses, we developed two models of CHD using fetal surgical techniques: 1) left pulmonary artery (LPA) ligation primarily resulting in increased PBF and 2) aortopulmonary shunt placement resulting in increased PBF and PAP. Hemodynamic, histologic, and molecular studies were performed on control, LPA, and shunt lambs as well as pulmonary artery endothelial cells (PAECs) derived from each. Physiologically, LPA, and to a greater extent shunt, lambs demonstrated an exaggerated increase in PAP in response to vasoconstricting stimuli compared with controls. These physiologic findings correlated with a pathologic increase in medial thickening in pulmonary arteries in shunt lambs but not in control or LPA lambs. Furthermore, in the setting of acutely increased afterload, the right ventricle of control and LPA but not shunt lambs demonstrates ventricular-vascular uncoupling and adverse ventricular-ventricular interactions. RNA sequencing revealed excellent separation between groups via both principal components analysis and unsupervised hierarchical clustering. In addition, we found hyperproliferation of PAECs from LPA lambs, and to a greater extent shunt lambs, with associated increased angiogenesis and decreased apoptosis in PAECs derived from shunt lambs. A further understanding of mechanical force-specific drivers of pulmonary artery pathology will enable development of precision therapeutics for pulmonary hypertension associated with CHD.


Subject(s)
Aorta/physiopathology , Hemodynamics , Pulmonary Artery/physiopathology , Pulmonary Heart Disease/physiopathology , Vascular Remodeling , Animals , Aorta/metabolism , Aorta/pathology , Arterial Pressure/physiology , Cell Proliferation , Coronary Occlusion/genetics , Coronary Occlusion/metabolism , Coronary Occlusion/physiopathology , Disease Models, Animal , Endothelial Cells/metabolism , Endothelial Cells/pathology , Female , Fetus , Heart Ventricles/metabolism , Heart Ventricles/pathology , Heart Ventricles/physiopathology , Humans , Lung/metabolism , Lung/pathology , Lung/physiopathology , Nitric Oxide/metabolism , Pregnancy , Primary Cell Culture , Pulmonary Arterial Hypertension/physiopathology , Pulmonary Artery/metabolism , Pulmonary Artery/pathology , Pulmonary Circulation/physiology , Pulmonary Heart Disease/congenital , Pulmonary Heart Disease/metabolism , Pulmonary Heart Disease/pathology , Sheep
5.
Cancer Res ; 77(9): 2464-2475, 2017 05 01.
Article in English | MEDLINE | ID: mdl-28235761

ABSTRACT

Genomic profiling is widely predicted to become a standard of care in clinical oncology, but more effective data sharing to accelerate progress in precision medicine will be required. Here, we describe cancer-associated genomic profiles from 18,004 unique adult cancers. The dataset was composed of 162 tumor subtypes including multiple rare and uncommon tumors. Comparison of alteration frequencies to The Cancer Genome Atlas identified some differences and suggested an enrichment of treatment-refractory samples in breast and lung cancer cohorts. To illustrate novelty within the dataset, we surveyed the genomic landscape of rare diseases and identified an increased frequency of NOTCH1 alterations in adenoid cystic carcinomas compared with previous studies. Analysis of tumor suppressor gene patterns revealed disease specificity for certain genes but broad inactivation of others. We identified multiple potentially druggable, novel and known kinase fusions in diseases beyond those in which they are currently recognized. Analysis of variants of unknown significance identified an enrichment of SMAD4 alterations in colon cancer and other rare alterations predicted to have functional impact. Analysis of established, clinically relevant alterations highlighted the spectrum of molecular changes for which testing is currently recommended, as well as opportunities for expansion of indications for use of approved targeted therapies. Overall, this dataset presents a new resource with which to investigate rare alterations and diseases, validate clinical relevance, and identify novel therapeutic targets. Cancer Res; 77(9); 2464-75. ©2017 AACR.


Subject(s)
Genetic Predisposition to Disease , Genomics , Neoplasm Proteins/genetics , Neoplasms/genetics , Gene Expression Profiling/methods , Gene Expression Regulation, Neoplastic/genetics , High-Throughput Nucleotide Sequencing , Humans , Molecular Targeted Therapy , Mutation , Neoplasm Proteins/biosynthesis , Neoplasms/pathology , Precision Medicine
SELECTION OF CITATIONS
SEARCH DETAIL
...